๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin)

โœ Scribed by Villani, Fabrizio; Galimberti, Milena; Comazzi, Roberto; Crippa, Flavio

Book ID
122626229
Publisher
Elsevier Science
Year
1989
Weight
518 KB
Volume
25
Category
Article
ISSN
0277-5379

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase I trial of 4-demethoxydaunorubicin
Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses
โœ S. Kaplan; C. Sessa; Y. Willems; M. A. Pacciarini; V. Tamassia; F. Cavalli ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Springer US ๐ŸŒ English โš– 454 KB

Twenty-four patients with a variety of solid tumors entered a Phase I trial with 4-demethoxydaunorubicin, a new analogue of daunorubicin. The drug was given as a single oral dose of 10-60 mg/m 2 repeated every 3-4 weeks. Leukopenia was the dose-limiting toxicity. Other toxic effects included mild t

A phase II study of oral idarubicin (4-d
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer
โœ Nicholas S. A. Stuart; Michael H. Cullen; Terrence J. Priestman; George R. P. Bl ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer ๐ŸŒ English โš– 352 KB

Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s